UltraGreen.ai's Ample Cash Position Set to Drive Further Growth, Market Penetration -- Market Talk

Dow Jones03-06 09:46

0146 GMT - UltraGreen.ai's ample net cash position of US$173 million is poised to drive further growth and market penetration, UOB Kay Hian analysts say in a research report. Management guided for 2026 revenue of US$170 million-US$190 million, supported by core business growth, the full-year effects of 2025 pricing initiatives, and further market expansion, the analysts note. The Singapore-based player in the fluorescence-guided surgery space is expected to maintain strong pricing power, supported by its market leadership and relatively low cost of indocyanine green as a percentage of overall surgical expenses. The brokerage keeps its buy rating on the stock, but trims the target price to US$1.95 from US$2.00 based on 26x 2026 P/E. Shares 1.3% lower at US$1.49. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

March 05, 2026 20:46 ET (01:46 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617505504?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617505504","market":"sg","top_or_hot":-1,"title":"UltraGreen.ai's Ample Cash Position Set to Drive Further Growth, Market Penetration -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0146 GMT - <a href=\"https://laohu8.com/S/ULG.SI\">UltraGreen.ai</a>'s ample net cash position of US$173 million is poised to drive further growth and market penetration, UOB Kay Hian analysts say in a research report. Management guided for 2026 revenue of US$170 million-US$190 million, supported by core business growth, the full-year effects of 2025 pricing initiatives, and further market expansion, the analysts note. The Singapore-based player in the fluorescence-guided surgery space is expected to maintain strong pricing power, supported by its market leadership and relatively low cost of indocyanine green as a percentage of overall surgical expenses. The brokerage keeps its buy rating on the stock, but trims the target price to US$1.95 from US$2.00 based on 26x 2026 P/E. Shares 1.3% lower at US$1.49. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 05, 2026 20:46 ET (01:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UltraGreen.ai's Ample Cash Position Set to Drive Further Growth, Market Penetration -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltraGreen.ai's Ample Cash Position Set to Drive Further Growth, Market Penetration -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-06 09:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0146 GMT - <a href=\"https://laohu8.com/S/ULG.SI\">UltraGreen.ai</a>'s ample net cash position of US$173 million is poised to drive further growth and market penetration, UOB Kay Hian analysts say in a research report. Management guided for 2026 revenue of US$170 million-US$190 million, supported by core business growth, the full-year effects of 2025 pricing initiatives, and further market expansion, the analysts note. The Singapore-based player in the fluorescence-guided surgery space is expected to maintain strong pricing power, supported by its market leadership and relatively low cost of indocyanine green as a percentage of overall surgical expenses. The brokerage keeps its buy rating on the stock, but trims the target price to US$1.95 from US$2.00 based on 26x 2026 P/E. Shares 1.3% lower at US$1.49. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 05, 2026 20:46 ET (01:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004311.SGD","symbol_name":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2617505504","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617505504","pubTimestamp":1772761560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0146 GMT - UltraGreen.ai's ample net cash position of US$173 million is poised to drive further growth and market penetration, UOB Kay Hian analysts say in a research report. Management guided for 2026 revenue of US$170 million-US$190 million, supported by core business growth, the full-year effects of 2025 pricing initiatives, and further market expansion, the analysts note. The Singapore-based player in the fluorescence-guided surgery space is expected to maintain strong pricing power, supported by its market leadership and relatively low cost of indocyanine green as a percentage of overall surgical expenses. The brokerage keeps its buy rating on the stock, but trims the target price to US$1.95 from US$2.00 based on 26x 2026 P/E. Shares 1.3% lower at US$1.49. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","LU0082770016.SGD":"HSBC GIF ASIA EX JAPAN EQUITY SMALLER COMPANIES \"AD\" (SGD) INC","LU0164939612.USD":"HSBC GIF ASIA EX JAPAN SMALLER CO. \"AC\" ACC","BK6103":"医疗保健用品","LU0620787316.HKD":"HSBC GIF ASIA EX JAPAN EQUITY SMALLER COMPANIES \"AD\" (HKD) INC","ULG.SI":"优创康智有限公司","LU0082770016.USD":"HSBC GIF ASIA EX JAPAN SMALLER CO. \"AD\" INC"},"translate_title":"UltraGreen.ai充足的现金头寸将推动进一步增长和市场渗透——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ULG.SI":0.9},"content_text":"0146 GMT - UltraGreen.ai's ample net cash position of US$173 million is poised to drive further growth and market penetration, UOB Kay Hian analysts say in a research report. Management guided for 2026 revenue of US$170 million-US$190 million, supported by core business growth, the full-year effects of 2025 pricing initiatives, and further market expansion, the analysts note. The Singapore-based player in the fluorescence-guided surgery space is expected to maintain strong pricing power, supported by its market leadership and relatively low cost of indocyanine green as a percentage of overall surgical expenses. The brokerage keeps its buy rating on the stock, but trims the target price to US$1.95 from US$2.00 based on 26x 2026 P/E. Shares 1.3% lower at US$1.49. (ronnie.harui@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2026 20:46 ET (01:46 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617505504","isCrawlerRequest":true}